Cell therapy for myelodysplastic syndromes

The invention provides methods for treating myelodysplasia syndrome (MDS). The invention is generally directed to reducing certain overt symptoms and disease-causing biological events in MDS by administering certain cells to a subject having MDS. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to affect these events. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for affecting these events.

Octrooi-publicatienummer: EP2992088

Jaar aanvraag: 2019

Jaar toekenning: 2019

Jaar van publicatie: 2019

Status: Toegewezen

Technologiedomeinen: Analyse van biologische materialen, Farmaceutische producten

Gevalideerd voor IOF-sleutel: Ja

Toegewezen aan: Associatie KULeuven